HEPA - Hepion Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7200
-0.2200 (-4.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.9400
Open4.9100
Bid4.5100 x 800
Ask5.2400 x 800
Day's Range4.6600 - 4.9100
52 Week Range2.0000 - 25.2000
Volume211,611
Avg. Volume1,090,622
Market Cap17.748M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-10.3330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
  • ACCESSWIRE

    Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases

    EDISON, NJ / ACCESSWIRE / February 19, 2020 / Hepion Pharmaceuticals, Inc. (HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells derived from five different organs. Collagen and fibronectin over-production from these types of cells cause fibrotic scarring of injured organs, and therefore these results suggest that CRV431 could exert anti-fibrotic activity across a range of diseases.

  • ACCESSWIRE

    Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

    EDISON, NJ / ACCESSWIRE / February 12, 2020 / Hepion Pharmaceuticals, Inc. (HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the advancement to the third dose level in its ongoing clinical trial of CRV431, a Phase 1 multiple ascending dose ("MAD") study. The open-label MAD study is designed to assess safety, tolerability and pharmacokinetics of CRV431, administered orally to healthy volunteers, once daily for 28 days. The study is examining doses of 75 mg, 150 mg, 225 mg and 300 mg, or higher in anticipation of progressing to a Phase 2 program.

  • ACCESSWIRE

    Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study

    In this specialized experimental model using human liver tissue, Hepion's drug candidate, CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading NASH drug candidates: obeticholic acid ("OCA", an FXR agonist), elafibranor (a PPARα/δ agonist), resmetirom (a THR-β agonist), and Aramchol (an SCD1 inhibitor). The study was conducted by FibroFind, a spin-out contract research company from the Fibrosis Research Group at Newcastle University, Newcastle Upon Tyne, UK.

  • ACCESSWIRE

    Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference

    EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising ...

  • ACCESSWIRE

    Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs

    EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that the peer-reviewed journal, Expert Opinion on Investigational Drugs, has published a paper entitled, "Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis." Cyclophilins are a family of modulatory enzymes and the target of Hepion's candidate drug, CRV431. Authored by Hepion's Chief Scientific Officer, Dr. Daren Ure; Senior Vice President of Drug Development, Dr. Daniel Trepanier; Senior Vice President of Clinical Pharmacology, Dr. Patrick Mayo; and CEO, Dr. Robert Foster, the paper is a comprehensive review of studies that have investigated cyclophilins in NASH and NASH-related liver disease.

  • Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII
    Zacks

    Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

    Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

  • Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF
    Zacks

    Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

    Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

  • Buy These 5 Stocks as New Analysts Initiate Coverage
    Zacks

    Buy These 5 Stocks as New Analysts Initiate Coverage

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • ACCESSWIRE

    Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

    EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the successful advancement to the next higher dose in its ongoing clinical trial of CRV431, a Phase 1 multiple ascending dose ("MAD") study. The open-label MAD study was initiated in the third quarter of 2019 to assess safety, tolerability and pharmacokinetics of CRV431 in healthy volunteers. The study is designed to examine doses of 75 mg, 150 mg, 225 mg and 300 mg, with the potential to assess higher doses, where CRV431 is administered orally, once daily for 28 days.

  • ACCESSWIRE

    Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

    EDISON, NJ / ACCESSWIRE / December 9, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising ...

  • ACCESSWIRE

    Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments

    EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that its CEO, Robert Foster, PharmD, PhD; Chief Scientific Officer, Daren Ure, PhD; Senior Vice President of Drug Development, Daniel Trepanier, PhD; and Senior Vice President of Clinical Pharmacology, Patrick Mayo, PhD have been appointed Adjunct Professors by the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences (the "Faculty"). "The Faculty is pleased to appoint Hepion's Drs. Foster, Ure, Trepanier and Mayo as Adjunct Professors in recognition of their discovery and past development of voclosporin, as well as their current work with CRV431 for the treatment of NASH and liver disease at Hepion," said Dr. Neal Davies, Dean of the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.

  • ACCESSWIRE

    Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), announced today that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 11:00 a.m. Eastern Time. Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis.

  • Benzinga

    Hepion Rips Higher After NASH Drug Confirms Antifibrotic Activity In Animal Study

    New Jersey-based Hepion said CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. FibrosIs is the formation of abnormally large amount of scar tissue in the liver when it attempts to repair and replace damaged cells. It could lead to cirrhosis.

  • ACCESSWIRE

    Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease

    EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that CRV431, an anti-fibrotic agent, prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. In this study, conducted by Physiogenex, S.A.S. (France), rats were administered the hepatotoxic compound, thioacetamide, for nine weeks to induce liver injury and fibrosis, in combination with either CRV431 or vehicle control for the entire study period.

  • ACCESSWIRE

    Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019

    EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising ...

  • ACCESSWIRE

    Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH

    CRV431 has Potently Reduced Fibrosis in all Experimental Models Tested To Date EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused ...

  • ACCESSWIRE

    Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit

    EDISON, NJ / ACCESSWIRE / October 23, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH") and chronic viral infection, today announced that its Chief Scientific Officer, Dr. Daren Ure, will present at the 3rd Annual NASH Summit taking place in London, UK from October 23-25, 2019. On October 25, 2019 at 9:20 a.m., Dr. Ure will highlight CRV431's potential as a treatment for NASH in a talk entitled, "CRV431, a Novel Drug Candidate for Liver Fibrosis." Dr. Ure will review several experimental models demonstrating the reduction of liver fibrosis as CRV431's most consistent effect.

  • ACCESSWIRE

    Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases

    CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the ...

  • ACCESSWIRE

    World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director

    EDISON, NJ / ACCESSWIRE / October 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising ...

  • ACCESSWIRE

    Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions

    EDISON, NJ / ACCESSWIRE / October 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH") and chronic viral infection, today announced that it has promoted three key team members with significant cyclophilin-based drug discovery and development experience to senior management positions in order to further position the Company to advance its lead candidate, CRV431. "Drs. Ure, Trepanier, Mayo and I have been working on cyclophilins, both independently and collaboratively, for the vast majority of our careers," said Dr. Robert Foster, the Company's CEO.

  • GlobeNewswire

    Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference

    EDISON, N.J., Sept. 04, 2019 -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • GlobeNewswire

    Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that it has received notification from the Nasdaq Hearings Panel (the “Panel”) that it has regained compliance with Nasdaq’s minimum shareholders’ equity rule, and is in compliance with other applicable requirements as set forth in the Panel’s decision dated May 3, 2019 and required for listing on The Nasdaq Stock Market. The Company's shares will continue to be traded on The Nasdaq Stock Market under the symbol HEPA.

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431

    Designed to assess safety, tolerability and pharmacokinetics of CRV431, this study is the third and final stage of CRV431's streamlined early clinical program, which was agreed upon with the U.S. Food and Drug Administration (“FDA”). “Having established safety and tolerability of CRV431 alone, as well as when co-dosed with TDF, this trial will monitor safety, tolerability and pharmacokinetics of CRV431 when administered repeatedly for 28 days in virally-suppressed HBV patients,” stated Dr. Foster, Hepion’s CEO.

  • GlobeNewswire

    Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that Dr. Stephen Harrison has joined its Scientific Advisory Board. “We are honored to have Dr. Harrison, an internationally recognized hepatologist (liver disease expert), join our Scientific Advisory Board,” commented Dr. Carol Brosgart, Clinical Professor of Medicine in the Divisions of Global Health Sciences, Biostatistics and Epidemiology in the Department of Medicine at the University of California, San Francisco and Chair of the Company’s Scientific Advisory Board.